

ESA SEMINAR 2022

29 APRIL - 1 MAY 2022









www.esaseminar.org.au

DELEGATE HANDBOOK

Hotel Grand

Chancellor

Launceston,

Tasmania

norditropin® flexpro®

Norditropin® FlexPro

somatropin (rbe)

is indicated for adults with severe GHD^{*1}

Designed with patients in mind

Store at room temperature (<25°C)

for up to 21 days

after first use1

Flexible storage¹

> [‡]Multi-dose, pre-filled pens with no mixing required^{1,2}

[§]Fine 0.025 mg increments closely tailor the daily dose to each patient¹

Tailored dosing[§]

GHD=growth hormone deficiency. *As diagnosed in the insulin tolerance test for GHD and defined by peak growth hormone concentrations of <2.5 ng/mL.¹ *All Norditropin[®] products must be refrigerated (between 2°C and 8°C) prior to use. While in use, the product may be stored for a maximum of 21 days below 25°C, alternatively stored for a maximum of 28 days in a refrigerator (between 2°C and 8°C).¹

PBS Information: This product is listed on the PBS as a Section 100 item. Refer to PBS Schedule for full authority information.

Please review Product Information before prescribing. The Product Information is available from www.novonordisk.com.au Minimum Product Information – Norditropin[®] FlexPro[®] 5mg, 10mg and 15mg, Norditropin[®] SimpleXx[®] 5mg, 10mg and 15mg (Somatropin (rbe). Biosynthetic human growth hormone). Indications: Children: Treatment of growth failure: due to pituitary growth hormone deficiency (GHD); girls due to gonadal dysgenesis (Turner Syndrome); due to chronic renal insufficiency where a child's height is on or less than the twenty-fifth percentile and growth velocity is on or less than the twenty-fifth percentile for bone age; and severe growth failure due to intrauterine growth retardation (IUGR). *Adults:* Treatment of severe GHD. Contraindications: Children with closed epiphyses; patients with retarded growth due to any cause other than pituitary GHD unless specifically indicated; patients with known hypersensitivity to excipients. Not to be used in patients with: evidence of active malignant tumours (discontinue in case of recurrent tumour growth); proliferative or perpoliferative diabetic retinopathy. Prade-Will syndrome who are severely obese or have respiratory impairment; or in children with chronic renal disease where there has been an episode of rejection in the twelve months following transplantation (discontinue in case of a new acute rejection episode). Not to be initiated in patients with acute critical illness due to complications following open heart surgery or abdominal surgery, multiple accident trauma, or those with acute respiratory failure. **Precautions:** Please review precautions section in full PI. Treatment should be directed by specialists experienced in the diagnosis and management of growth hormone deficiency. Jumar Syndrome, chronic renal disease, IUGR/SGA (Small for Gestational Age). Do not mix with other medicines. Patients with increased risk for diabetes mellitus should be followed. Very rare cases of severe/recurrent headache, visual symptoms, nausea and/or vomiting, a

References: 1. Norditropin[®] FlexPro[®] Product Information. 2. Fuchs GS *et al. Clin Ther* 2009;31:2906–14. Novo Nordisk[®] Pharmaceuticals Pty Ltd ABN 40 002 879 996. Level 10, 118 Mount Street, North Sydney NSW 2060. www.novonordisk.com.au FlexPro[®] and Norditropin[®] are registered trademarks owned by Novo Nordisk Health Care AG and the Apis bull logo is a registered trademark of Novo Nordisk A/S. ©2021 Novo Nordisk Healthcare AG, Zurich, Switzerland. AU21NP00023. SSW. NOR-002365-00. Date of preparation: August 2021.



THE ANNUAL ENDOCRINE SOCIETY OF AUSTRALIA SEMINAR 2022 ACKNOWLEDGES THE SUPPORT OF

GOLD SPONSORS





SILVER SPONSORS







COFFEE CART SPONSOR



EXHIBITORS







oharmaceuticals

sanofi

BRANDING PARTNERS







CONTENTS

CONFERENCE SPONSORS	3
WELCOME	4
SOCIETY & CONFERENCE SECRETARIAT	4
GENERAL INFORMATION	5
SOCIAL FUNCTIONS	8
INVITED PLEANRY SPEAKER	10
INVITED SYMPOSIUM SPEAKERS	10
ESA SEMINAR PROGRAM FRIDAY 29 TH APRIL SATURDAY 30 TH APRIL SUNDAY 1 ST MAY	17 17 18 19
LAUNCESTON	20
SPONSORS & EXHIBITORS	23
EXHIBITION FLOOR PLAN	25
IN PERSON ATTENDANCE LISTING	27
NOTES	31



The ESA is a community and for our next Seminar meeting we hope you will all come to a new type of meeting; one that enhances our learning while breaking with tradition.

Launceston is a city of contrasts and we aim to showcase the best of Tasmania while bringing you the best of endocrinology. With the main theme of adrenal disease, our Plenary speaker is Prof Gary Hammer, the 2020 US Endocrine Society President. We hope you will come as a show of support to the global endocrine community and to celebrate his time down under.

In addition to fantastic plenary presentations and sessions with local experts, there will be case presentations and panel discussions. In particular, the program will cover topics including: diabetes, thyroid, bone and calcium, and will pay homage to the Tasman 1 kindred MEN1 publications.

The major difference will lie in the feel of the meeting. Launceston is regional. It is Australia's third oldest city and has undergone significant urban renewal. The architecture remains elegant in line with its history, but there is also a thriving art and design element. In addition, the food and wine scene is excellent, with seriously committed providores turning out some of the finest produce in Australia. It has been a while and we would love to bring our community together to celebrate our society.

We have arranged a variety of accommodations throughout the city, with the conference facilities located at the heart of it all, The Hotel Grand Chancellor. Bring your walking shoes (and umbrella) to make the most of all that we have planned.

Come and support our society while we support the thriving town of Launceston!

Dr Anna Story and Dr Diana Learoyd,

Co-Convenors on behalf of ESA



Dr Anna Story Director and Endocrinologist, Northern Sydney Endocrine Centre and Sydney Medical School



A/Prof Diana Learoyd Endocrinologist GenesisCare North Shore and Sydney Medical School

SOCIETY & CONFERENCE SECRETARIAT

Endocrine Society of Australia

145 Macquarie Street Sydney, NSW 2000 Contact Person: Ivone Johnson Ph: 0414 454 085 ijohnson@endocrinesociety.org.au www.endocrinesociety.org.au Conference Secretariat – ASN Events Unit 9/397 Smith Street, Fitzroy VIC 3065 Contact Person: Jim Fawcett Phone 0449 251 659 Jim.f@asnevents.net.au www.asn.events

GENERAL INFORMATION

CONFERENCE VENUE

Hotel Grand Chancellor 29 Cameron St Launceston, Tasmania Phone: (+61) 03 6334 3434

PARKING

Onsite, adjacent to the hotel. Car parking rates start from \$6.00 per vehicle per day, subject to availability.

REGISTRATION DESK

The registration desk will be situated in the Pre-Function Area, outside the Conference Centre (Chancellor 1 & 2) and attended as follows: Friday 29th April, 11:00 am – 5:15 pm | Saturday 30th April, 07:00 am – 1:00 pm | Sunday 1 May, 08:30 am – 12:15 pm. The Exhibition will be open from 12:30 pm on Friday 29th April.

CONFERENCE MEETING ROOM & EXHIBITION

All Plenary and Symposium sessions will take place within the Chancellor 1 Room. The Exhibition will be held in the Chancellor 2 Room. Chancellor 1 & 2 are adjactent to each other and known as the Conference Centre.

The Conference Meeting Room is supported by



COFFEE CART

Complimentary barrista coffee will be served within the Exhibition (Chancellor 2) at the start of each day and within catered breaks.



NAME BADGE

Your name badge is your official pass to all scientific and catered sessions. Ensure you wear your name badge at all times and if misplaced, please see the staff at the registration desk for a replacement.

REGISTRATION INCLUSION

Conference delegates receive the following services as part of their registration:

Access to all sessions on the day(s) of your registration, Conference Program Booklet, Name Tag, Catering during lunch and morning/afternoon tea breaks & a ticket to the Welcome Function.

WIRELESS INTERNET

Delegates can connect to the free Wi-Fi within the Grand Chancellor.

WIFI-Username/network: EVENTS | Password: HGCL

SUNDAY LUGGAGE STORAGE

If you are planning on departing from the Hotel Grand Chancellor on the Sunday after the Seminar Meeting, you can store your luggage directly with the front office reception team.

ESA Seminar 2022 Booklet



SUNDAY BUS TRANSFER

The conference offers a bus transfer (\$15) from the Hotel Grand Chancellor to Launceston Airport on Sunday 1st May. The transfer will depart at approximately 1.00pm and arrive at the airport around 1.30pm. Tickets need to be pre-booked and are available for purchase from the registration desk.

SPEAKER PRESENTATIONS

Speakers are encouraged to load their presentations in Chancellor 1 at least one session before their talk to avoid any last-minute rushes. An AV Technician will be able to assist presenters. The standard AV set up for all presentations will be data projection using MSPowerPoint. All presentations will be run from a PC.

PARENT'S ROOM

The existence of the Virtual Platform will allow parents to watch the presentations live from the comfort of their own rooms or to catch up at a later time if more convenient

VIRTUAL PLATFORM

All delegates – both virtual and in-person- have access to the virtual conference platform to view sessions live and on-demand. The recordings will remain available to watch for up to 12 months after the meeting.

The virtual conference platform is accessible via this link: www.pheedloop.com/ESASeminar2022/virtual/. Please contact the conference secretariat if you haven't received your login details.

MOBILE PHONES

Please ensure your mobile phone is turned off during sessions.

SPECIAL MEAL REQUESTS

If you have requested a special meal (dietary requirements), please identify yourself to the venue staff. All requests have been passed onto the venue and will be catered for accordingly.

SMOKING

Smoking is not permitted in the venue.

INSURANCE

The hosts and organisers are not responsible for personal accidents, any travel costs, or the loss of private property and will not be liable for any claims. Delegates requiring insurance should make their own arrangements.

DISCLAIMER

The hosts, organisers and participating societies are not responsible for, or represented by, the opinions expressed by participants in either the sessions or their written abstracts.

THE POWER TO ACCOMPLISH MORE[†] *Above and beyond glycaemic control^{1,2*}

^The ONLY ORAL T2D treatment indicated for PREVENTION OF CV DEATH

in patients with T2D and established CV disease (CAD, PAD, MI or stroke) on top of standard of care^{1#}

* Standard of care included antihypertensives, lipid-lowering agents, anticoagulants and glucose-lowering therapies.²



PBS Information: JARDIANCE®: Authority Required (STREAMLINED). Type 2 Diabetes.

Code 7506 - Add-on to metformin or SU. Code 4991 - Add-on to Insulin. Code 5629 - Triple therapy (with metformin and SU). Code 7528 - Triple therapy, initial treatment (with metformin + DPP4i). Code 7495 - Triple therapy, continuing treatment (with metformin + DPP4i). Refer to PBS Schedule for full Authority Required Information.

BEFORE PRESCRIBING, PLEASE REVIEW THE FULL PRODUCT INFORMATION AVAILABLE FROM BOEHRINGER INGELHEIM AT WWW.BOEHRINGER-INGELHEIM.COM.AU/PI.

JARDIANCE[®] (empagliflozin) 10 mg, 25 mg film-coated tablets. INDICATIONS: <u>Glycaemic control</u>: Treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic control in adults as: *Monotherapy* - When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance; *Add-on combination therapy* - With other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. <u>Prevention of cardiovascular (CV) death</u>: In patients with T2DM and established CV disease to reduce the risk of CV death. To prevent CV deaths, Jardiance should be used in conjunction with other measures to reduce CV risk in line with the current standard of care. **CONTRAINDICATIONS:** Hypersensitivity to empagliflozin or any of the excipients; for the treatment of T2DM - JARDIANCE should not be used in patients with severe renal impairment (eGFR <30mL/min/1.73m²) as glycaemic efficacy depends on renal function; rare hereditary conditions of galactose intolerance, e.g. galactosaemia. **PRECAUTIONS:** Patients with type 1 diabetes; ketoacidosis; surgery; patients with T2DM - contraindicated when eGFR is below 30mL/min/1.73m²; monitoring of renal function is recommended; consider discontinuation in patients with recurrent complicated urinary tract infections (UTIs); necrotising fasciitis of the perineum (Fournier's gangrene); patients for whom a drop in BP could pose a risk (e.g. those with known CV disease, on diuretics, have a history of hypotension, or agel ≥75 years); pregnancy; lactation; children (<18 years). **INTERACTIONS:** Diuretics - may add to diuretic effect of thiazide and loop diuretics; insulin and sulfonylurea (SU) - may increase the risk of hypoglycaemia; interference with 1,5-anhydrogluciol assay. **ADVERSE REACTIONS:** <u>Very common</u>: hypoglycaemia (combination with metformin and allong lightin); UTIs; increased with or without food. The recommended starting doo

CAD=coronary artery disease; CV=cardiovascular; MI=myocardial infarction; PAD=peripheral artery disease.

References: 1. JARDIANCE® Product Information 23 December 2021. 2. Zinman B et al. N Engl J Med 2015;373:2117-28.



Boehringer Ingelheim Pty Limited, ABN 52 000 452 308, 78 Waterloo Road, North Ryde, NSW 2113, Australia Copyright © 2022. PC-AU-102555. Prepared January 2022. BOEH1481.

Eli Lilly Australia Pty Limited, ABN 39 000 233 992, 112 Wharf Road, West Ryde, NSW 2114, Australia Copyright © 2022.



SOCIAL FUNCTIONS

WELCOME RECEPTION - FRIDAY 29TH APRIL

Start off ESA Seminar 2022 with a bang and join us for the Welcome Function on Friday night!

Time: 5:15 PM - 6:15 PM | Location: Hotel Grand Chancellor | Price: Included for delegates | \$15 per additional ticket

The Welcome Reception is supported by



A NIGHT OF CULINARY ADVENTURE AT ALIDA - FRIDAY 29TH APRIL


After the Welcome Reception, let us take you on a journey filled with local culinary delights! Join us at Alida (formerly known as Penny Royal Wine Bar and Restaurant) for a uniquely Tasmanian food and wine experience, with a menu embracing Tassie's seafood and beef heritage, complimented by Joseph Chromy wines and local spirits. The venue is conveniently located between the picturesque Cataract Gorge and Launceston's CBD (walking distance from Hotel Grand Chancellor) and boasts wonderful water views from the adjoining boardwalk.

Time: 6:30 PM - 8:30 PM | Location: Alida Restaurant (Penny Royal complex) | 1 Bridge Rd, Launceston (15-minute walk from Hotel Grand Chancellor) | Price: \$25 per person

CONFERENCE DINNER - SATURDAY 30TH APRIL

For the Conference Dinner on Saturday Night, we are delighted to have booked out Cataract on Paterson, a beautiful venue boasting a quirky, yet elegant industrial design paired with contemporary cuisine and polished service. The menu focuses on fresh Tasmanian produce, featuring high-quality grass-fed beef from Great Southern Pinnacle and a seafood tasting plate, containing locally caught fresh Tasmanian oysters and scallops.

Time: 7:00PM – late | Location: Cataract of Paterson Restaurant - 135 Paterson Street, Launceston | Price: \$50 for delegates | \$90 per additional ticket



This year, our dinner speaker will be Dr James Haddy from University of Tasmania with a talk on the effects of stress on reproduction. Dr James Haddy's area of expertise is in conducting field and laboratory based research on the population dynamics, life history ecology and physiology (reproduction and stress endocrinology) of aquatic fauna. The majority of his work has focused on important recreational and commercial species of fish, crustaceans and molluscs. As a result, James has expertise in fisheries research and stock assessment modelling, from the initial collection of data (field biology) through to computer intensive quantitative modelling. Currently, James teaches undergraduate units covering aquatic biology, fisheries biology and population dynamics, fisheries assessment and field research techniques for aquatic ecosystems.



INTRODUCING IPSEN ASSIST®

A support program sponsored by Ipsen Pty Ltd for patients prescribed Somatuline® Autogel® (lanreotide)

Work with your patients to identify the most appropriate program service for them:

In-home, self-injection*

Training for self injection provided to a patient or their caregiver in the home*

Three training sessions (via live video call or face-to-face)

*For patients controlled on Somatuline Autogel, and who are both motivated and competent to perform the injection following training

Option to switch to the local-clinic service at any time

Administration at a local GP clinic

- Training for a local GP or nurse at the patient's nominated clinic
- Arrangements taken care of by an Ipsen Assist coordinator

The reassurance of administration by a known and trusted healthcare professional and the opportunity to coordinate visits with regular GP appointments

Learn more about Ipsen Assist

- Visit the Ipsen Medical Stand on Friday or Saturday
- Call Ipsen Assist on 1800 477 366 or email support@ipsenassist.com
- Talk to us further about your needs including our nurse home injection service

To enrol patients go to ipsenassist.com and use access code SOM101

PBS Information: Authority required (STREAMLINED). This product is a highly specialized drug listed on the PBS as a Section 100 item. Refer to PBS Schedule for full authority information.

Before prescribing please refer to the full Product Information, which is available from Ipsen Medical Information. Ph: 1800 317 033 or from <u>http://www.guildlink.com.au/gc/ws/ipsen/pi.cfm?product=ispsatgi</u>

Somatuline* Autogel*: Lanreotide as acetate in a pre-filled syringe (60, 90 and 120 mg). Indications: Treatment of acromegaly when circulating growth hormone and IGF-1 levels remain abnormal after surgery and/or radiotherapy or in patients who have failed dopamine agonist therapy; the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours; the treatment of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adult patients with unresectable locally advanced or metastatic disease. Contraindications: Lactation: hypersensitivity to lanreotide or related peptides or other excipients. Precautions: May experience hypoglycaemia or hyperglycaemia (monitor blood glucose levels); slight decrease in thyroid function; may reduce gall bladder motility (recommend gall bladder echography); postmarketing reports of cholecystitis, cholangitis and pancreatitis requiring cholecystectomy; discontinue use if complications of cholelithiasis are suspected; monitor kidney and liver function; may reduce heart rate in patients without an underlying cardiac problem (monitor heart rate; caution with treatment initiation in patients with bradycardia). Not recommended for use in children. See full PI for further information. Interactions with Other Medicines: Reduced absorption of cyclosporin A, decreased bioavailability of cyclosporine, increased availability of bromocriptine, additive bradycardia effects with beta-blockers, decreased clearance of quinidine, terfenadine. Effect on driving / using machinery: If affected by dizziness do not drive or use machinery. Adverse Effects: Very common: diarrhoea or loose stools, abdominal pain, cholelithiasis; Common: hypoglycaemia, hyperglycaemia, diabetes mellitus aggravated, fatigue, lethargy, asthenia, dizziness, headache, sinus bradycardia, alopecia, hypotrichosis, nausea, vomiting, dyspepsia, flatulence, abdominal distension, abdominal discomfort, constipation, biliary dilatation, steatorrhoea, injection site reactions (pain, mass, induration, nodule, pruritis), laboratory investigation changes, weight decreased, decreased appetite, musculo-skeletal pain, myalgia. See full PI for further information. Dose: Acromegaly: For first time treatment the starting dose is 60 mg every 28 days; for patients previously treated with Somatuline LA every 14, 10 or 7 days, the starting dose is 60 mg, 90 mg or 120 mg respectively every 28 days. Dosage should be adjusted according to GH and/or IGF-1 response. Well controlled patients can be treated with 120mg every 42-56 days. Carcinoid Syndrome: 60 to 120 mg every 28 days, adjusted according to symptomatic relief. GEP-NETs: 120mg every 28 days; treatment should be continued for as long as needed for tumour control. Administration: Deep subcutaneous injection in the superior external quadrant of the buttock (healthcare professional or carer); or the upper, outer thigh (self-administration). Decision for injection by patient or carer to be made by a healthcare professional. Patients must be controlled on Somatuline Autogel and patients/carers must be motivated, competent and trained to inject. Storage: 2°C-8°C

*For patients controlled on Somatuline Autogel, and who are both motivated and competent to perform the injection following training. *Îpsen Assist, Somatuline and Autogel are registered trade marks of Ipsen Pty Ltd. Ipsen Assist Support Program is an initiative of Ipsen Pty Ltd. ™ Cohere is a trade mark of Partizan Health. For further information about Somatuline* Autogel*, please contact Ipsen Pty Ltd, ABN 47 095 036 909, Level 2, Building 4, Brandon Office Park, 540 Springvale Road, Glen Waverley, VIC 3150 Australia. **T:** +61 (0)3 8544 8100 **F:** +61 (0)3 9562 5152 **E:** info@ipsen.com.au **W:** www.ipsen.com.au Date of preparation: April 2022 SOM-AU-001012





INVITED PLENARY SPEAKER



Prof Gary Hammer- University of Michigan, USA

Gary D. Hammer, M.D., Ph.D. is a Professor in the Departments of Internal Medicine (Metabolism, Endocrinology & Diabetes), Cell & Developmental Biology, and Molecular & Integrative Physiology at the University of Michigan (UofM). Before arriving in Michigan in 1999, he obtained his M.D. and Ph.D. in Neuroscience from Tufts University and completed his residency in Internal Medicine followed by a clinical fellowship in Endocrinology and a post-doctoral fellowship with Holly Ingraham at the University of California, San Francisco. He currently serves as the Director of the Endocrine Oncology Program in the Comprehensive Cancer Center at UofM where he holds the Millie Schembechler

Professorship in Adrenal Cancer. He has brokered the recent renaissance of the current Michigan team of adrenal scientists that includes a who's who in the clinical and basic study of adrenal disease. He received the UofM Jerome Conn Award for Outstanding Research in Internal Medicine, the Endocrine Society Edwin B. Astwood Award for Outstanding Research in Endocrinology and is a member of the American Society for Clinical Investigation and Association of American Physicians.

INVITED SYMPOSIUM SPEAKERS



Prof John Burgess

Royal Hobart Hospital & University of Tasmania

Professor John Burgess (MBBS, PhD, MD, FRACP) is a consultant endocrinologist at the Royal Hobart Hospital, the Professor of Endocrinology at University of Tasmania, and Director of the Endocrinology Laboratory at the RHH. After attaining Fellowship of the Royal Australasian College of Physicians, he completed an MD examining factors influencing clinical expression of tumours in Multiple Endocrine Neoplasia type 1, and subsequently a PhD investigating the epidemiology of papillary thyroid carcinoma. He maintains an active research interest in relation to both endocrine neoplastic conditions as well as iodine

nutrition and thyroid disease. Dr Burgess is the physician in charge of the Endocrine Neoplasia Clinic at the RHH and he continues to published extensively in the field MEN 1 pathogenesis, screening and clinical management.



Prof Rory Clifton-Bligh

Royal North Shore Hospital, NSW

Prof Roderick Clifton-Bligh is Head of the Department of Endocrinology at Royal North Shore Hospital, and professor of Medicine at the University of Sydney. He completed a PhD in the genetics of thyroid disorders at the University of Cambridge. He now supervises dual research groups, one of which focuses on the genetics of endocrine neoplasms, and the other on metabolic bone disease. The Cancer Genetics Unit studies the molecular bases of thyroid cancer, phaechromocytoma/paraganglioma syndromes, adrenal cancer, and pituitary neoplasms. The Metabolic Bone Research Unit studies calcium-sensing receptor

gene mutations and FGF23 biology. His scope of clinical practice remains broad. He has co-supervised 10 completed PhDs, including five Endocrinologists. He maintains a strong involvement in teaching and mentoring young physicians.



A/Prof Samantha Fraser-Bell

Sydney Eye Hospital and Royal North Shore Hospital, NSW

Samantha Fraser-Bell is an Associate Professor in the discipline of Ophthalmology at the University of Sydney. She is actively involved in clinical research, running a weekly research clinic at the Macula Research Unit, Save Sight Institute, and Sydney Eye Hospital, where she has been an investigator for more than 50 retinal clinical trials, including several investigator initiated trials in the management of diabetic macular oedema. Samantha has authored more than 100 peer-reviewed publications. Other significant positions held include: Medical retina and uveitis specialist at Royal North Shore Hospital; Deputy

Director of Clinical Trials, Save Sight Institute, University of Sydney; Medical Retina subeditor for Clinical and Experimental Ophthalmology; Ophthalmic Research Institute of Australia (ORIA) board member and secretary of the ORIA grant review panel; International Macula Society member; and co-Director of Sydney Eye Hospital Medical Retina fellowship program.



A/Prof Christian Girgis

Royal North Shore and Westmead Hospitals, NSW

A/Prof Christian Girgis is a staff endocrinologist at Royal North Shore and Westmead Hospitals in Sydney. He completed a PhD in 2014 at the Garvan Institute of Medical Research on vitamin D signaling and skeletal muscle. He was subsequently awarded an NHMRC post-doctoral research fellowship and in 2015, was a visiting scholar to the Salk institute of Biological studies, USA. Currently, his clinical work focuses on metabolic bone disease, calcium disorders and osteoporosis re-fracture prevention. He conducts translational research in broad areas of musculoskeletal health and is involved in medical education as an

associate professor at the University of Sydney.



A/Prof Sarah Glastras

Royal North Shore Hospital, NSW

Dr Sarah Glastras is a clinician researcher who works as a Staff Specialist in Endocrinology at the Royal North Shore Hospital, Sydney and holds a conjoint appointment as an academic Senior Lecturer at the University of Sydney. She also consults in a busy private endocrinology practice in St Leonards. Dr Glastras completed her PhD studies in 2016 at the Kolling Institute of Medical Research, University of Sydney on the role of maternal obesity in predisposing offspring towards chronic disease, and continues foetal programming research as a NHMRC Early Career Fellow. In addition to her basic science research, she is

involved in many clinical studies in the areas of diabetes and obesity, with a special interest in pregnancy. She is leading a clinical study investigating the role of biomarkers in predicting preeclampsia in women with type 1 diabetes in pregnancy, funded by a JDRF Mentored Clinician Researcher Fellowship and supported by Diabetes Australia. She chairs the Complex Medical Management in Pregnancy Working Group within the Northern Sydney Local Health District.



Dr Caroline Jung

St Vincent's Hospital, Royal Women's Hospital, The Royal Victorian Eye and Ear HospitaL, VIC

Dr Caroline Jung graduated from the University of Melbourne with Honours in 1999. She completed specialist physician training in Endocrinology in 2006. Her PhD (University of Melbourne 2011) evaluated the hypothalamic-pituitary-adrenal axis during pregnancy and in people with obesity, diabetes, Cushing's syndrome and adrenal insufficiency. Dr Jung has received several awards and grants for her research, including the Bryan Hudson Clinical Endocrinology award and the ESA Seed grant. Dr Jung works at St Vincent's Hospital, Royal Women's Hospital and at

the Royal Victorian Eye and Ear Hospital in Melbourne. She is a Senior Lecturer at the University of Melbourne.



A/Prof Don Mcleod

Royal Brisbane & Womens's Hospital, QLD

Don McLeod is a Senior Staff Specialist in Endocrinology at the Royal Brisbane & Women's Hospital, Honorary Senior Research Officer at QIMR Berghofer Medical Research Institute, and Associate Professor of the University of Queensland. After gaining his FRACP in 2010, Don undertook a Master of Public Health in Quantitative Methods at Harvard School of Public Health, Boston, USA, followed by a research fellowship in thyroid cancer in the Division of Endocrinology and Metabolism at The Johns Hopkins University School of Medicine in Baltimore, USA. He was awarded his PhD in thyroid epidemiology in 2015. Don's main research interests are thyroid

cancer and autoimmunity, including Graves' disease, and is supported by a Queensland Advancing Clinical Research Fellowship and a Metro North Clinician Research Fellowship. He serves as an Editorial Board member of Thyroid and Associate Editor of Clinical Thyroidology. Don's contribution to education has also been recognized with the UQ Medical Society Award for Excellence in Clinical Teaching.



Dr Emily Meyer

University of Adelaide and Royal Adelaide Hospital, SA

Emily Meyer is an Endocrinologist currently completing her PhD the University of Adelaide and Royal Adelaide Hospital. She has a passion for clinical research, having embarked on a PhD in corticosteroid-binding globulin (CBG) in septic shock and was successful in being awarded the AR Clarkson Scholarship, Royal Adelaide Hospital Research Fund. Emily has published a number of reviews and research papers in the field, demonstrating an association between a reduction in high-affinity CBG and septic shock mortality. As part of her PhD, she has developed a novel homogenous ligand binding assay using Surface Plasmon Resonance (SPR) technology. Using this

technique, she has characterised the binding affinities of both high- and low-affinity CBG to a library of steroid ligands, at temperatures and at physiological and acidaemic pH to mimic the pathophysiological conditions of septic shock. Emily has presented these findings at both the ESA and ENDO annual meetings, receiving the ESA IPSEN and Endocrine Society's Early Career Travel Awards. She has also published on SGLT2 inhibitor associated diabetic ketoacidosis (DKA) in the perioperative period, received a Australian Diabetes Association (ADS) Clinical Poster award and work which has informed ADS and ANZCA released clinical management guidelines. Research is ongoing to address incidence and risk of SGLT2 inhibitor associated DKA in the perioperative setting with the aim to further guide clinical practice.



A/Prof Frances Milat

Hudson Institute & Monash University, VIC

Associate Professor Frances Milat is an Endocrinologist, Head of the Metabolic Bone Services at Monash Health, Head of the Metabolic Bone Research Group at the Hudson Institute and Research Fellow in the Department of Medicine, School of Clinical Sciences, Monash University. After graduating from Medicine at Monash University in 1996, she pursued her clinical and research interest in endocrinology and metabolic bone disorders, completing her doctorate in PTH and Wnt pathway action in bone at St Vincent's Institute. Fran is committed to improving patient care through clinical research, with interests in osteoporosis in chronic disease and osteoporosis in young adults. She is involved in the

supervision of research students as well as medical student and postgraduate teaching. A/Prof Frances Milat has been awarded several prizes for clinical and research excellence. She is also involved in osteoporosis and endocrine guideline development and serves on national committees in both a clinical and research capacity.



Dr Julie Miller

The Royal Melbourne Hospital & Australia/New Zealand Endocrine Surgeons, VIC

A/Professor. Miller is a specialist surgeon with specific expertise in endocrine surgery. Originally from the United States, she became a fully qualified surgeon in New York City before moving to Australia in 2001. She is a consultant surgeon at The Royal Melbourne Hospital and Epworth Freemason's Hospital, and former Clinical Sub-Dean for Surgical Education at the University of Melbourne. Professor Miller serves as the President of Australia/New Zealand Endocrine Surgeons, and Head of the Endocrine Section of the Royal Australasian College of Surgeons. She is Head of the Thyroid and Endocrine Tumour Group of the

Royal Melbourne Hospital, and directs the Thyroid Cancer Multidisciplinary Care Conference. She has a special interest and expertise in minimally invasive parathyroid surgery, as well as thyroid and adrenal surgery. In 2011, A/Professor. Miller was the first surgeon in Victoria to perform a PRA (posterior retroperitoneoscopic adrenalectomy). This approach to the adrenal gland is relatively painless, so it benefits the patient in terms of faster recovery. Most patients have no need for prescription pain tablets. In 2017, she became the first surgeon in Australia to offer non-surgical ablation of benign thyroid cysts using medical grade ethanol, thereby allowing patients with large, symptomatic cysts to be treated without surgery. A/Professor. Miller is a sought after speaker and has given many invited lectures nationally and internationally on her areas of expertise.



Dr Barbora Paldus

St Vincent's Hospital, VIC

Dr Barbora Paldus is an Endocrinologist and Research Fellow at St Vincent's Hospital, Melbourne. Dr Barb is passionate about improving the lives of people with type 1 diabetes (T1D) and has a special interest in the application of novel diabetes technologies and algorithms to the management of T1D. As a technology and sports enthusiast, she has undertaken tertiary studies in mathematics and computer programming and is currently completing a PhD through the University of Melbourne focusing on advancing closed loop insulin delivery (artificial pancreas) and other novel technologies for T1D management during exercise.





Dr Michael Thompson

Royal Hobart Hospital, TAS

Michael Thompson is an Advanced Trainee in Endocrinology based at the and PhD candidate at the Menzies Research Institute Tasmania supported by a NHMRC scholarship. Michael has served as Chief Registrar for the Royal Hobart Hospital, Support Registrar and Medical Education Advisor for the Postgraduate Medical Council of Tasmania and Editor-in-Chief of the Australian Medical Student Journal. He has presented as a finalist for the ESA Bryan Hudson Clinical Endocrinology award (2018 & 2019) and been recipient of the RACP Tasmanian Trainee Research prize (2014 & 2018) and inaugural Tasmanian AMA President's

Award for Excellence (2015). He is a current lecturer and examiner at the University of Tasmania. Recreational pursuits include hiking and long distance trail running.



Prof David Torpy

Royal Adelaide Hospital, SA

David Torpy is a Consultant Endocrinologist at the Royal Adelaide Hospital. His research interests predominantly involve studies of the hypothalamic-pituitaryadrenal axis and stress. Recent specific areas have included corticosteroidbinding globulin (CBG) genetic variants and their effect on the stress response, immune-HPA interactions involving CBG and cortisol delivery in inflammatory states, adrenal function in septic shock, maternal cortisolaemia in complicated pregnancies, inherited forms of adrenal dysfunction causing Cushing's and cortisone dosing and well-being in Addison's disease and studies of adrenal crisis.



Dr Venessa Tsang

Royal North Shore Hospital, NSW

Dr Venessa Tsang is an Endocrinology Staff Specialist at Royal North Shore Hospital. She has an interest in endocrine cancers, having completed a PhD on the Molecular Pathogenesis of Phaeochromocytoma and Paraganglioma at the Kolling Institute of Medical Research, University of Sydney, in 2015. She is currently involved in a number of clinical trials and investigator led research looking at advanced and metastatic thyroid cancer. She has published and presented on basic and clinical research in thyroid cancer, phaeochromocytoma and paraganglioma and other familial endocrine syndromes, endocrine adverse

effects of immune check point inhibitors, functional neuroendocrine tumours, and type 3c diabetes secondary to pancreatic surgery. She is strongly involved with medical education, having co-ordinated the MD project for Northern Clinical School and involved in Endocrine Assessment for the Sydney Medical Programme. She is currently a supervisor for MD student project and PhD Student.



Dr Annabelle Hayes

Royal Adelaide Hospital, SA

Annabelle is a second year Advanced Trainee in Endocrinology at Flinders Medical Centre, and previously at the Royal Adelaide Hospital. She has an interest in Pituitary and Adrenal Endocrinology and is undergoing research in cortisol metabolism and diabetes in Indigenous populations. She has served in the role of Chief Medical Resident and continues to be involved in medical student education.

ESA Seminar 2022 Booklet



eSHINE OFFERS QUALITY & FLEXIBILITY¹

for your patients with acromegaly or neuroendocrine tumours

Patients prescribed Sandostatin® LAR® (Octreotide) have the option to receive the following services on eSHINE:



To find out more about the eSHINE Patient Support Program, contact your Novartis representative.

To register for eSHINE and start enrolling patients please visit: www.eshinesupportprogram.com.au or scan the QR code.



Scan to register

Sandostatin® LAR®: AUSTRALIA

Sandostatin® LAR® PBS Information: Section 100. Public & Private Hospital and Community Access Authority Required (STREAMLINED). Refer to PBS Schedule for full Authority Information.

See approved Product Information before prescribing. TGA approved Product Information available on request. Sandostatin® LAR® (octreotide)

See approved Product Information before prescribing. TGA Approved Product Information available on request. Indications: •Symptomatic control and reduction of GH and IGF-1 plasma levels in acromegaly patients inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment but who are adequately controlled on s.c. treatment with Sandostatin, unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. •Relief of symptoms associated with carcinoid tumours with features of carcinoid syndrome and vasoactive intestinal peptide secreting tumours (VIPomas) in patients who are adequately controlled on s.c. treatment with Sandostatin. Treatment of patients with progression of well-differentiated, advanced neuroendocrine

tumours of the midgut or suspected midgut origin. Dosage and administration: Read the enclosed directions before use. Deep intragluteal injection. Initial dose 20 mg every 4 weeks for 3 months. Dose to be adjusted according to response (10 to 30 mg every 4 weeks). The recommended dose of Sandostatin LAR for the treatment of advanced neuroendocrine tumours of the midgut or suspected midgut origin is 30mg every 4 weeks Contraindications: Hypersensitivity to octreotide or any components of the formulation.

Precautions: Antidiabetics, beta-blockers, calcium channel blockers or agents to control fluid and electrolyte balance, dose adjustment may be necessary. Ultrasonic examination of the gallbladder at timed intervals recommended. Monitor pituitary tumour size expansion. Sudden escape from symptomatic control has occurred using s.c. Sandostatin. Sandostatin LAR is likely to affect glucose regulation. Monitor patients with Type I diabetes mellitus and patients with a more state parallely before the parallely better the par

Interactions: Reduced absorption of cyclosporin and delayed absorption of cimetidine; effect on absorption of orally administered drugs should be considered. Dose adjustments of drugs such as antidiabetics, beta-blockers, calcium channel blockers, or agents to control fluid and electrolyte balance, may be necessary. Increased bioavailability of bromocriptine. Caution with concomitant use of drugs mainly metabolised by CYP3A4 and which have a low therapeutic index (e.g. quinidine).

Side effects: Very common: diarrhoea, abdominal pain, nausea, constipation, flatulence, headache, cholelithiasis, hyperglycaemia, and injection-site reactions (including local pain and occasionally swelling, irritation and rash) Side effects: Very common: diarmoet, abdominal bloating, steatorrhoea, loose stools, discolouration of faeces, dizziness, hypothyroidism, thyroid disorder (e.g. decreased thyroid stimulating and mathematical part in doct about and trash). Common: dyspepsia, vomiting, asthenia, abdominal bloating, steatorrhoea, loose stools, discolouration of faeces, dizziness, hypothyroidism, thyroid disorder (e.g. decreased thyroid stimulating hormone [TSH], decreased Total T4, and decreased Free T4), cholecystitis, biliary sludge, hypothylirubinaemia, hypoglycaemia, impairment of glucose tolerance, anorexia, elevated transaminase levels, pruritus, rash, alopecia, dyspnoea, and bradycardia. Uncommon: dehydration, and tachycardia. Rare: gastrointestinal side effects (may resemble acute intestinal obstruction, with progressive abdominal distension, severe epigastric pain, abdominal tenderness and guarding), acute pancreatitis and cholelithiasis-induced pancreatitis in patients taking s.c. Sandostatin. Post-marketing reports: anaphylaxis, isolated cases of anaphylactic shock, allergy/hypersensitivity reactions, urticaria, acute pancreatitis, acute hepatitis without cholestasis, cholestatic hepatitis, cholestasis, jaundice, cholestatic jaundice, arrhythmia, thrombocytopenia, increased alkaline phosphatase levels, and increased gamma glutamyl transferase levels.

(smsL210820m). Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park NSW 2113. Ph (02) 9805 3555. ® Registered Trademark. For the most up to date Product Information go to https://www.novartis.com.au/products/healthcare-professionals/products/ Internal Document Code: smsL210820m is based on PI smsL210820i



Abbreviation: eSHINE, Electronic Sandostatin LAR Home INjection ServicE Patient Support Program; LAR, long-acting repeatable. Reference:1. Wakelin K. Patient reported experiences of the burden of neuroendocrine tumors and impact of eSHINE Patient Support Program on patient quality of life. Asia-Pac J Clin Oncol. Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park NSW 2113. Ph (02) 9805 3555. ® Registered Trademark Item AU-20020. Date of preparation: March 2022.

FRIDAY 29TH APRIL

11:00 AM	REGISTATION OPENS
12:30 PM	EXHIBITION OPENS
	WELCOME
1:15 PM - 1:30 PM	Dr Anna Story and A/Prof Diana Learoyd
	SYMPOSIUM #1 DIABETES Chair: Dr Sally Abell
1:30 PM - 2:00 PM	New type 1 diabetes technologies; Dr Barbora Paldus
	Presentation supported by Novo Nordisk
2:00 PM - 2:30 PM	Metabolic issues surrounding pregnancy; A/Prof Sarah Glastras
2:30 PM - 3:00 PM	Diabetic eye disease update; A/Prof Samantha Fraser-Bell
3:00 PM - 3:30 PM	AFTERNOON TEA
	SYMPOSIUM #2 THYROID Chair: Dr Kris Park
3:30 PM - 4:00 PM	lodine- refractory thyroid cancer; Dr Venessa Tsang
4:00 PM - 4:30 PM	Troublesome forms of thyroiditis; Dr Don McLeod
	PLENARY 1 Chair: Prof David Torpy
4:30 PM - 5:15 PM	Adreno-cortical cancer; What's New Today/Where is Hope? Prof Gary Hammer
5:15 PM - 6:15 PM	WELCOME FUNCTION
	Supported by Pfizer
6:30 PM - 8:30 PM	A NIGHT OF CULINARY ADVENTURE AT ALIDA (PENNY ROYAL)

SATURDAY 30TH APRIL

7:00 AM	REGISTRATION OPENS
	BREAKFAST SYMPOSIUM
7:30 AM - 8:30 AM	Focus Group: Developing a Decision Aid for Patients with Low-Risk Thyroid Cancer Dr Chris Rowe & Dr Christine O'Neill
	SYMPOSIUM #3 ADRENAL Chair: A/Prof Morton Burt
8:30 AM - 9:00 AM	Issues with cortisol measurements from a clinician's perspective; Dr Caroline Jung
9:00 AM - 9:30 AM	Adrenal insufficiency management; Prof David Torpy
9:30 AM - 10:00 AM	What's New with the Adrenal Medulla? Prof Rory Clifton-Bligh
10:00 AM - 10:30 AM	MORNING TEA
	PLENARY 2 Chair: Dr Anna Story
10:30 AM - 11:15 AM	The Enigma of the SHH Adrenal Progenitor; Prof Gary Hammer
	DIFFICULT ADRENAL CASES and TOPICS
	Chair: Prof David Torpy Panel: Prof Gary Hammer, Prof Rory Clifton-Bligh and Dr Caroline Jung
11:15 AM - 11:35 AM	
11:15 AM - 11:35 AM 11:35 AM - 12:00 PM	Panel: Prof Gary Hammer, Prof Rory Clifton-Bligh and Dr Caroline Jung
	Panel: Prof Gary Hammer, Prof Rory Clifton-Bligh and Dr Caroline JungA tale of two sisters; Prof David TorpyAdjunctive medical treatment for adrenal tumours with histological features
11:35 AM - 12:00 PM	 Panel: Prof Gary Hammer, Prof Rory Clifton-Bligh and Dr Caroline Jung A tale of two sisters; Prof David Torpy Adjunctive medical treatment for adrenal tumours with histological features suspicious for ACC; Dr Annabelle Hayes
11:35 AM - 12:00 PM 12:00 PM - 12:30 PM	 Panel: Prof Gary Hammer, Prof Rory Clifton-Bligh and Dr Caroline Jung A tale of two sisters; Prof David Torpy Adjunctive medical treatment for adrenal tumours with histological features suspicious for ACC; Dr Annabelle Hayes Cortisol in Severe Illness; Dr Emily Meyer
11:35 AM - 12:00 PM 12:00 PM - 12:30 PM 12:30 PM - 1:00 PM	Panel: Prof Gary Hammer, Prof Rory Clifton-Bligh and Dr Caroline Jung A tale of two sisters; Prof David Torpy Adjunctive medical treatment for adrenal tumours with histological features suspicious for ACC; Dr Annabelle Hayes Cortisol in Severe Illness; Dr Emily Meyer LEADERSHIP AND MENTORSHIP BY PROF GARY HAMMER + LUNCH

Supported by 🐌 NOVARTIS

SUNDAY 1ST MAY

6:00 AM – 8:00 AM	CATARACT GORGE WALK
8:30 AM	REGISTRATION OPENS
	SYMPOSIUM #4 BONE AND PARATHYROID Chair: Dr Syndia Lazarus
9:00 AM - 9:30 AM	Timely intervention in osteoporosis; A/Prof Fran Milat
	Presentation supported by Amgen
9:30 AM - 10:00 AM	Complications of osteoporosis therapies; A/Prof Christian Girgis
10:00 AM - 10:30 AM	Management of hyper and hypoparathyroidism; A/Prof Julie Miller
10:30 AM - 11:00AM	MORNING TEA
	FINAL SYMPOSIUM #5 Chairs: A/Prof Diana Learoyd & Dr Amanda Seabrook
11:00 AM - 11:30 AM	Adrenal surgery update; A/Prof Julie Miller
11:30 AM - 12:15 PM	Lessons learned from the Tasman1 kindred; Prof John Burgess & Dr Michael Thompson
12:15 PM - 1:00 PM	LUNCH
1:00 PM	BUSES TO AIRPORT DEPART

LAUNCESTON

We call it Launnie.

There's something that lies beneath the surface here that defines us as a city. You may not see it at first, but the moment you step foot here, you feel it. You sense it in the architecture, in the streets, out in nature, between the people — an undercurrent — born from generations of hard-work, curiosity, community, resilience, independence. The meeting place of three waterways, our beautiful city has been a cultural hub and gastronomic centre for more than two thousand generations. The first to love this land were the Tasmanian Aboriginal people, who have one of the oldest continuing cultures in the world. Today, around 110,000 people call Launnie home. There are no tourists here – just locals and temporary locals still discovering their true north. Our city is human scale. A series of green and wild spaces linked by heritage streetscapes

and thoughtful adaptions. A real blend of old-world and new, tradition and innovation. We've honed our craft and aren't scared to experiment either – there's always something exciting bubbling away. Our natural and built heritage, food, wine (and spirit) have drawn together a diverse community of makers, artisans, storytellers and nature lovers from all over the world. Culture takes many forms, and we've made life's simple pleasures an art. We aren't much into big-city swagger, but you'll find plenty of charm. Our close-knit community always has time for people, time to connect. Here, the farm gate is the local store, nature is our playground, and the cellar never runs dry.

Launnie Favourites

Architecture along the ages

Launceston is a jewel-box of built styles and design – best explored on foot, camera in-hand. Here is a list of some of the city's most iconic buildings and storied streetscapes, for visitors to enjoy at their own pace. All locations are closely connected in and around the CBD by flat paths and offer curious stories of ingenuity and innovation that have helped build the real story of Launnie. Visit some in a couple of hours or all in a couple of days and don't forget to stop and enjoy the eateries, boutiques, parks and galleries along the way.





Supported by U NOVARTIS

Holyman House, Brisbane Street.

Built in 1936, this iconic Art Deco building originally housed Holyman Company's automobile showroom as well as shipping and aviation interests. The buildings sleek curves and neon-lit spire embodied the owners bold, futuristic vision.

Kings Bridge, Trevallyn Road.

Dating from 1864, Kings Bridge links to the accessible paths of the magnificent Cataract Gorge Reserve. Fabricated in Manchester, England and transported to Launceston, it was assembled on a pontoon and floated into position before being lowered onto its abutments on the receding tide.



Prince's Square, Elizabeth Street.

Established in 1858 on a disused brickfield, Prince's Square is known for its dappled light and beautiful Val d'Osne Fountain. Its manicured symmetry belies earlier use as a rubbish dump, military parade ground, and rowdy political meeting-place. **The Post Office, Cameron Street.**

Launceston Post Shop was built between 1886 – 1899 in the Queen Anne architectural style. The stout tower (nicknamed the pepper pot) was added a few years later by public subscription, and the clock installed just in time to celebrate Launceston's centenary in 1906.

Dining in Launceston

Eats of Charles Street

About mid-way along Charles Street in Launceston's centre is a string of epicurean attractions to tempt the seasoned gastronome or casual foodie. Each eatery offers an individual spin on produce sourced fresh from around the region. Havilah wine bar is a place to stop for a glass of Tamar Valley vino and piece of cheese or settle in for an evening of tailored drops and dishes. Next door is Geronimo, a luxurious space to indulge in family-style dishes and share plates. If you enjoy Asian fusion, try the big, hugely satisfying flavours of Monsoon or Buddhai Thai - both offer takeaway, too. Over the road from these restaurants is Prince's Square, a locally-loved green space featuring a fountain with a most fortuitous story and beds of colour. Further south along Charles Street are brunch hot spots Mondello and Elaia cafes, as well as the Sporties pub for a parmi or Burger Got Soul for takeaways. Coffee is never far away, either - try Prince's Square Bar or Aroma's. Bread and Butter is just around the corner: try their renowned morning buns. Charles Street Greengrocer and Landfall butcher offer backyard-fresh morsels and supermarkets and boutique shopping such as Ecoco aren't far away, either.

Supported by U NOVARTIS

Eats in general

A few other must-samples while you're in Launnie... Caffeine: Valley Coffee, Amelia's, Sweet Brew, Off Centre Snacks: Turkish Tukka, Small Grain, Alberto's, Earthy Eats, Veg Out Dinner: Pachinko, Curry Club, Black Cow Bistro, Kosaten, Stelo Drinks: Bar Two, Saint John Craft Beer, Royal Oak Picnic basket: Harvest Market, Alps and Amici, Trevallyn Grocer





Waterway Wanderings

Along the edge of kanamaluka/Tamar River and the North Esk River are various, distinctive experiences for the whole family to discover and learn from - all accessible along flat paths and in one day. Begin at Queen Victoria Museum where you'll learn about the intricate and unique biodiversity of what lies beneath the surface of these internationally-significant waterways. Next stop is discovering more than a century of mechanical knowledge at the National Automobile Museum then onto Peppers Silos for a fresh-baked snack followed by bursts of energy at the adjacent Riverbend Park playground.



This incredible facility offers space for all

ages and abilities and connects to the stretch of restaurants including Mud Bar and Levee Food Co at Seaport Precinct. The Seaport Boardwalk winds along the banks of kanamaluka, which you can enjoy from different perspectives on a Tamar River Cruise or by ascending the famed zig-zag track. Another playground, fish'n'chips or the acclaimed eatery Stillwater are further attractions to be savoured along the way to the Cataract Gorge, an unparalleled natural attraction and sacred meeting place for Tasmanian Aboriginal communities for tens of thousands of years. An exceptional day out in Launnie.

Uncover more experiences in and around Launnie at www.visitnortherntasmania.com.au

ANZBMS-MEPSA-ANZORS 2022

SAVE THE DATE 1st – 4th AUGUST

Gold Coast Convention & Exhibition Centre

Combined Scientific Meetings of the Australian and New Zealand Bone and Mineral Society, The Molecular and Experimental Pathology Society of Australasia & The Australian and New Zealand Orthopaedic Research Society.

Abstract Submission Deadline: Friday 3rd June Earlybird Registration Deadline: Friday 3rd June

www.anzbms-mepsa-anzors.org







AMGEN

BOOTHS 10 & 11

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

AUDIT4 SOFTWARE

BOOTH 6

BOOTH 4

BOOTH 5

Audit4 software, developed by S4S Pty Ltd (an Australian Company) is unique because it was developed by medical specialists for medical specialists. It has led to a greater efficiency for the medical specialist as the software is designed the way the clinician thinks. Every field in Audit4 - clinical (diagnoses, medications, pathology results etc), demographic and patient reported, is auditable – giving the clinicians and hospital outpatient clinics unprecedented ability to instantly analyse their own clinical data, measure clinical workloads and patient outcomes. Nearly one-third of all Endocrinologists around Australia use Audit4 for billing, appointments and their clinical practice including electronic scripts and integration with My Health Record.

The Australian Addison's Disease Association Inc. provides a valuable resource on Addison's disease/adrenal insufficiency to the medical community, patients and carers. As a non-profit organisation with 350 plus members, the Association strives to improve outcomes for people with this rare condition by providing up-to-date information and ongoing support.

Email: info@addisons.org.au

Website: www.addisons.org.au/medicalprofessional/

AUSTRALIAN ADDISON'S DISEASE ASSOCIATION INC



BESINS HEALTHCARE

Besins Healthcare has been an innovator in hormone replacement therapy for four generations. Over the last 50 years, Besins Healthcare has established a strong reputation internationally for the development and production of novel agents for the treatment of hypogonadism, menopause, luteal support in IVF, contraception, and other gynaecological, fertility and obstetrical conditions.





b NOVARTIS

BOEHRINGER INGELHEIM AND ELI LILLY AND COMPANY ALLIANCE

COFFEE CART SPONSOR

Two companies; one commitment to diabetes. Since 2012, Boehringer Ingelheim and Eli Lilly as an Alliance have brought to market a number of new therapies, based on years of research and development. Supporting multiple international clinical trials, new evidence has been

generated to improve the management and outcomes for patients with type 2 diabetes. By partnering with the medical and healthcare community, we will continue to contribute these improvements as two companies, with one commitment to diabetes.

Find out more at www.boehringer-ingelheim.com.au and www.lilly.com.au

EISAI

Eisai is derived from the Japanese word for 'health product' and, here at Eisai, we discover, develop and market innovative, high quality medicines throughout the world. In Australia, Neurology and Oncology are our primary specialty areas.

For more information about Eisai, or our products, please visit www.eisai.com.au or email Contact_Australia@eisai.net

INOVA PHARMACEUTICALS

iNova Pharmaceuticals markets and sells a range of industry-leading and trusted consumer healthcare products and prescription medicines across Asia, Africa, and Australasia. Our vision is to improve people's health and well-being within the therapeutic areas of weight management, cough, cold & flu, pain management, health supplements, dermatology, sun care, and female health products.

IPSEN

Ipsen provides specialty medicines and quality services to healthcare professionals and their patients suffering from debilitating diseases. At Ipsen, our passion is improving the lives of patients. We do this by working together to build partnerships based on trust and mutual respect with Healthcare Professionals. We deliver tailored solutions through our agility and innovation and we strive to be even better tomorrow than we are today.

Ipsen Pty Ltd is the Australian affiliate of a global biotech company.

Supported by U NOVARTIS

NOVARTIS

Novartis is the largest Australian medicines company, improving the lives of more than 2.8 million patients across Australia and New Zealand. From generics to gene therapy, we are committed to accelerating patient access to life saving treatments. We are reimagining medicine by using innovative science and technology to address challenging healthcare issues and our rich pipeline has 200+ projects in development and an industry leading clinical trial footprint in Australia.









BOOTH 2

BOOTH 7

BOOTH 1

BOOTH 13





NOVO NORDISK

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

PFIZER ENDOCRINE CARE

BOOTH 12

BOOTH 3

Breakthroughs that change patients' lives™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global health care portfolio includes human biologic and small molecule medicines and vaccines, as well as many of the world's best-known consumer products.

For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

sanofi

SANOFI

Sanofi is driven by science and the patients whose health and wellbeing depend on us. Our purpose is to bring hope, relief and cures to patients around the world by researching, developing and manufacturing medicines and vaccines, and by accelerating access to scientific innovation.

5 Catering 6 3 7 2 11 12 βm 1 10 13 8 Catering 9 Coffe

EXHIBITION FLOOR PLAN

Booth Number	Organisation
1	Ipsen
2	iNova Pharmaceuticals
3	Sanofi
4	Australian Addison's Disease Association Inc.
5	Besins Healthcare
6	Audit4 Software
7	Eisai
8 & 9	Novo Nordisk
10 & 11	Amgen Australia
12	Pfizer Endocrine Care
13	Novartis



Give patients with Growth Hormone Deficiency peace of mind for the long term¹⁻⁴

Offer your adult patients with GHD the benefits of GH replacement therapy with Genotropin:

- Results from baseline to 12 months (n=163)²
 - Increased lean body mass (p<0.001)
 - Reduced total skin fold thickness (p=0.003)
 - Decreased LDL-cholesterol (p=0.019)
- 25 years clinical use in >16000 adults⁴

PBS Information: Authority required. Refer to PBS Schedule for full authority information.

BEFORE PRESCRIBING PLEASE REVIEW FULL PRODUCT INFORMATION AVAILABLE FROM WWW.PFIZER.COM.AU/PRODUCTS/GENOTROPIN.

GENOTROPIN®/GENOTROPIN GoQuick® (somatropin [rbe]) 5 mg, 5.3 mg and 12 mg Injection. GENOTROPIN® MiniQuick® (somatropin [rbe]) 0.2 mg – 2.0 mg Injections. **Therapeutic indications:** Short stature (GH deficiency); growth disturbances associated with Turner syndrome or chronic renal insufficiency (CRI); Prader-Willi syndrome (PWS); severe GH deficiency in adults. **Dosage and method of administration**: Administer by subcutaneous (sc) injection. Vary injection site to prevent lipoatrophy. Dosage is individual and gradually titrated. Give weekly dose in divided doses, 6-7 times per week. **Recommended weekly doses in children**: *GHD*: Initial dose of 0.175 to 0.245 mg/kg body weight. *Turner syndrome and CRI*: 0.3 to 0.35 mg/ kg body weight. *PWS*: 0.245 to 0.35 mg/kg body weight. **Adults with GHD**: 0.04 mg/kg/week gradually increased to 0.08 mg/kg/week (maximum), divided into 7 daily sc injections. Women may require higher doses than men, meaning that women, especially those on oral oestrogen replacement may be undertreated. Monitor growth rate and measure biochemical markers (e.g. IGF-1) regularly. Dose requirements may decline with age. See PI for details. **Contraindications:** Active turnours (anti-turnour therapy must be complete); closed epiphyses; metacresol hypersensitivity; acute critical illness; severe obesity or severe respiratory impairment in PWS. **Special warnings and precautions for use:** PWS; myositis; diabetes (or risk factors); hypoadrenalism; oral oestrogen therapy; malignancy relapse; leukaemia; pituitary turnour or pituitary hormone deficiencies; thyroid hormone replacement therapy; hypothyroidism; pregnancy; lactation. See PI for details. **Interactions with other medicines and other forms of interactions:** Concomitant glucocorticoids; CYP3A4 metabolised drugs; women on oral oestrogen replacement. **Adverse effects:** Symptoms of fluid retention: peripheral oedema, face oedema, musculoskeletal stiffness, arthralgia, myalgia, paraesthesia; antibody formation; injection site reactions (children); c

Abbreviations: GHD, growth hormone deficiency

References: 1. GENOTROPIN® Approved Product Information. 2. Cuneo RC, et al. J Clin Endocrinol Metab 1998; 83(1): 107–16. 3. Allen DB et al. Eur J Endocrinol 2015; 174(2): PI–P9. 4. Pfizer International Metabolic Database (KIMS). Available at https://medicaloutcomes.pfizer.com/kims. Last accessed March 2021.



IN PERSON ATTENDANCE LISTING

Sally Abell Royal Hobart Hospital, TAS, Australia

Jeff Ahn Ryde Hospital, NSW, Australia

Aleena Ali Austin Health, VIC, Australia

Carolyn Allan Hudson Institute of Medical Research, VIC, Australia

Lisa Anderson Amgen Australia, NSW, Australia

Marion Arnott Novo Nordisk, NSW, Australia

Richard Arnott Alfred Hospital, VIC, Australia

Sally Atichison Amgen Australia, NSW, Australia

Michele Bardin The Northern Hospital, VIC, Australia

Katherine Benson Sydney Adventist Hospital, NSW, Australia

Ray Bissett Ipsen, VIC, Australia

Kenrick Blaker My Specialists Sydney, NSW, Australia

Mitsi Blazos Alfred Hospital, VIC, Australia

Lance Boyd-Clark Novartis Pharmaceuticals, NSW, Australia

Pierre-Nicolas Boyer Royal Brisbane and Women's Hospital, QLD, Australia

Ingrid Bretherton Austin and Western Health, VIC, Australia

Emily Brooks Queensland Health, QLD, Australia

Felicity Brooks Sanofi, NSW, Australia

Warren Brooks Ipsen Pty Ltd, VIC, Australia

John Burgess Royal Hobart Hospital, TAS, Australia

ESA Seminar 2022 Booklet

Morton Burt Flinders Medical Centre, SA, Australia

Karen Byrne Boehringer Ingelheim, NSW, Australia

Joanne Campbell Launceston general hospital, TAS, Australia

Sarah Catford Alfred Health, VIC, Australia

Thora Chai Westmead Hospital, NSW, Australia

Anindita Chakrabarti Barwon Health, VIC, Australia

Christopher Chan Westmead Hospital, NSW, Australia

Julie Chemmanam Women's and Children's Hospital, SA, Australia

Thomas Chesterman Endocrine Consultants SA, SA, Australia

Ada Cheung Austin Health, VIC, Australia

Rebekah Chew Northern Adelaide Local Health Network, SA, Australia

Cellina Ching Dept of Diabetes & Endocrinology, Westmead Hospital, NSW, Australia

Chito Chua iNova Pharmaceuticals, NSW, Australia

Irene Chum Besins Healthcare Australia, NSW, Australia

Roderick Clifton-Bligh Royal North Shore Hospital, NSW, Australia

Luke Conway Cairns Hospital, QLD, Australia

Bridget Cooper The Canberra Hospital, ACT, Australia

Caitlin Corkhill ACT Health, ACT, Australia

Amanda Cox Austin/Northern Health, VIC, Australia Owen Cox Recordati Rare Diseases Australia, NSW, Australia

Emma Croker John Hunter Hospital, NSW, Australia

Abhay Daniel Tweed Hospital, NSW, Australia

Jessica Deitch Western Health, VIC, Australia

Yi Shan Der Royal Brisbane and Women's Hospital, QLD, Australia

Lida Derakhshan Novo Nordisk, NSW, Australia

Caroline Dillistone Ipsen Pty Ltd, VIC, Australia

Samantha Donaldson Spring Hill Endocrinology, QLD, Australia

Peter Donovan Royal Brisbane and Women's Hospital, QLD, Australia

Alastair Downes Novo Nordisk, NSW, Australia

Yang Du Royal Adelaide Hospital, SA, Australia

Anna Duke Blacktown Mt Druitt Hospital, NSW, Australia

Lisa Eabry Ipsen, VIC, Australia

Jade Eccles-Smith The Royal Brisbane and Women's Hospital, QLD, Australia

Audrey Eer University of Melbourne, VIC, Australia

Hannah Farquhar Logan Hospital, QLD, Australia

Yvonne Feng Private practice, NSW, Australia

Prishila Fookeerah Westmead hospital, NSW, Australia

Patrice Forner St Vincent's Hospital Sydney, NSW, Australia Rebecca Foskey St Vincent's Hospital Melbourne, VIC, Australia

Samantha Fraser-Bell Sydney Eye Hospital, Royal North Shore Hospital, University of Sydney, NSW, Australia

Mary Freeman Sutherland Hospital, NSW, Australia

Aviva Frydman Austin Health, VIC, Australia

Sue Lyn Goh Eastern Health, VIC, Australia

Joanna Gong Melbourne Health, VIC, Australia

Debbie Gordon western Health and Baker IDI, VIC, Australia

Marjy Grealish Prince of Wales Hospital, NSW, Australia

Akhil Gupta Western Sydney University, NSW, Australia

Kathryn Hackman Alfred Hospital, VIC, Australia

James Haddy University of Tasmania, TAS, Australia

Bella Halim St Vincent's Hospital Melbourne, VIC, Australia

Shane Hamblin Western Health, VIC, Australia

Gary Hammer University of Michigan, MICHIGAN, United States

Amy Harding Bendigo Health, VIC, Australia

Jeffrey Hassall Amgen Australia, NSW, Australia

Kate Hawke Royal Brisbane & Women's Hospital, QLD, Australia

Annabelle Hayes Royal Adelaide Hospital/Flinders Medical Centre, SA, Australia

Jinwen He Mater Hospital, QLD, Australia

ESA Seminar 2022 Booklet

Diane Helliger Eisai Australia, VIC, Australia

Elise Hickey Wollongong Hospital, NSW, Australia

Ken Ho Ryde Endocrinology, NSW, Australia

Winnie Ho Launceston General Hospital, TAS, Australia

Gerard Hoey Novo Nordisk, NSW, Australia

Jane Holmes-Walker Westmead Hospital, NSW, Australia

Sashie Howpage Dubbo Base Hospital, NSW, Australia

Su Win Htike Bankstown-Lidcombe Hospital, NSW, Australia

Annie Hung Albury Wodonga Health, NSW, Australia

David Hurley Royal Perth Hospital, WA, Australia

Elena Jackson Royal Hobart Hospital, TAS, Australia

Veena Jayadev Concord Hospital, NSW, Australia

Anju Joham Monash Health, VIC, Australia

Rachel Johnston Royal Brisbane and Women's Hospital, QLD, Australia

Caroline Jung St Vincent's Hospital, Fitzroy, VIC, Australia

Ni Ni Khin Fraser Coast Health Services, QLD, Australia

Teresa Kho Novo Nordisk, NSW, Australia

Albert Kim Garvan Institute of Medical Research, NSW, Australia

Mark Kotowicz Deakin University School of Medicine, VIC, Australia

Pinar Kozan Orange Specialis Clinic, NSW, Australia Benjamin Kwan Concord Repatriation General Hospital, NSW, Australia

Hilda Lam Monash Health, VIC, Australia

Christopher Lamb Inova Pharmaceuticals, NSW, Australia

Lik-Hui (William) Lau Austin Health, VIC, Australia

Sue Lynn Lau Westmead Hospital, NSW, Australia

Syndia Lazarus Royal Brisbane and Women's Hospital, QLD, Australia

Diana Learoyd GenesisCare, NSW, Australia

I-Lynn Lee Western Health, VIC, Australia

Nele Lenders St Vincent's Hospital, NSW, Australia

Georgia Lenehan Sanofi, NSW, Australia

Brian Liew Launceston General Hospital, TAS, Australia

Mike Lin Concord Hospital, NSW, Australia

Nay Aung Lin Miranda Medical Centre, NSW, Australia

Matthew Luttrell Wollongong Hospital, NSW, Australia

Judy Luu John Hunter Hospital, NSW, Australia

Hamish Maltby Novo Nordisk, NSW, Australia

Gayatri Mani Novartis Pharmaceuticals, NSW, Australia

Mani Manoharan Liverpool Hospital, NSW, Australia

Abdul Mardli Amgen Australia, NSW, Australia

Anthony Mason Eisai Australia, VIC, Australia

Manik Mayadunne Liverpool Hospital, NSW, Australia

Supported by U NOVARTIS

Ann McCormack St Vincent's Hospital, NSW, Australia

Rob McGregor Ipsen, VIC, Australia

Don McLeod Royal Brisbane & Women's Hospital, QLD, Australia

Michael McNamara Barwon Health, VIC, Australia

Emily Meyer Royal Adelaide Hospital, SA, Australia

Frances Milat Monash Health, VIC, Australia

Julie Miller Royal Melbourne Hospital, VIC, Australia

Kisha Mokdad Novo Nordisk, NSW, Australia

Michael Mond Monash Health, VIC, Australia

Bronwyn Monro Australian Addisons Disease Association Inc, NSW, Australia

James Monro Australian Addison's Diseases Association Inc, NSW, Australia

Claire Morbey Hunter Diabetes Centre, NSW, Australia

Christopher Muir St. Vincent's Hospital, Sydney, NSW, Australia

Ben Nash Royal Hobart Hospital, TAS, Australia

Nadia Navie Ipsen Pty Ltd, VIC, Australia

Aditi Nevgi Monash Health, VIC, Australia

Darrell Ng Novo Nordisk, NSW, Australia

Elisabeth Ng Monash Health, VIC, Australia

Hang Dieu Thuy Nguyen Launceston General Hospital, TAS, Australia

Huajing Ni St George Hospital, NSW, Australia

ESA Seminar 2022 Booklet

Kellie Novak Ipsen Pty Ltd, VIC, Australia

May Lea Ong Western Health, VIC, Australia

Suja Padmanabhan Westmead Hospital, NSW, Australia

Barbora Paldus St Vincent's Hospital, VIC, Australia

Jim Panagiotidis Amgen Australia, VIC, Australia

Suren Parihar Boehringer Ingelheim Ltd, VIC, Australia

Kris Park Nepean Hospital, NSW, Australia

Sarah Parry The University of Sydney, NSW, Australia

Sarah Pattison Austin Health, VIC, Australia

Erin Paul Austin Health, VIC, Australia

Julian Pavey Mater Hospitsl, QLD, Australia

Ben Peatt Amgen Australia, NSW, Australia

Cecilia Pham Austin Health, VIC, Australia

Racheal Pinheiro Pfizer, VIC, Australia

Connie Pleash Ipsen Pty Ltd, VIC, Australia

Sandi Powell Royal Hobart Hospital, TAS, Australia

Ann Poynten Prince of Wales Hospital, NSW, Australia

Louise Prentice University of Tasmania, TAS, Australia

Gaurav Puri Fremantle Hospital, WA, Australia

Qi Yang Damien Qi The Royal Melbourne Hospital, VIC, Australia

Armi Rahimi Amgen, NSW, Australia Rohit Rajagopal Campbelltown Hospital, NSW, Australia

Kate Rassie Monash Health/ Monash University, VIC, Australia

Lisa Raven St Vincent's Hospital, NSW, Australia

Mayurapriya Raviskanthan Monash Health, VIC, Australia

Karen Rees Amgen Australia, NSW, Australia

Yoon Ji Jina Rhou Westmead Hospital, Sydney, NSW, Australia

Richa Richa Gold Coast Hospital, QLD, Australia

Tim Richards Novo Nordisk, NSW, Australia

Emily Robertson Alfred Health, VIC, Australia

Duncan Robinson Besins Healthcare, NSW, Australia

Christopher Rowe John Hunter Hospital, NSW, Australia

Sina Saberian Novo Nordisk, NSW, Australia

Anuradha Sakthivel Eastern Health, VIC, Australia

Junhong Sang Dalian Jinxi Medical Technology Co., Ltd, LIAONING, China

Dhanya Sanjeev Self employed, NSW, Australia

Stella Sarlos Monash Health, VIC, Australia

Mark Savage Bendigo Health, VIC, Australia

Robert Schmidli Canberra Hospital, ACT, Australia

Gillian Scott Royal Perth Hospital, WA, Australia

Amanda Seabrook Westmead Hospital, NSW, Australia

Anthony Shelton Recordati Rare Diseases Australia, NSW, Australia Luisa Siannis Ipsen Pty Ltd, VIC, Australia

Ie-Wen Sim Eastern Health, Monash Health, VIC, Australia

Goldy Singh Novartis Pharmaceuticals, NSW, Australia

Howard Smith Westmead Hospital, NSW, Australia

Georgia Soldatos Monash Health, VIC, Australia

Bianca St John Tasmanian Health Service, TAS, Australia

Desiree Stagg Novartis Pharmaceuticals, NSW, Australia

Lara Stallard-Taylor Novo Nordisk, NSW, Australia

Georgie Stilwell Royal Hobart Hospital, TAS, Australia

Anna Story Northern Sydney Endocrine Centre, NSW, Australia

Felicity Stringer Barwon Health, VIC, Australia

Chelsea Tan Bendigo Health, VIC, Australia

Chin Yao Tan Monash Health, VIC, Australia

Yong Mong Tan Townsville University Hospital, QLD, Australia

Mark Taylor Ipsen, VIC, Australia Nadia Tejani Fairfield Hospital, NSW, Australia

Jessie Teng St Vincent's Health, Eastern Health, VIC, Australia

Shailja Tewari The Canterbury Hospital, NSW, Australia

Christina Theodore Royal Adelaide Hospital, SA, Australia

Eleanor Thong Monash Health, VIC, Australia

David Torpy Royal Adelaide Hospital, SA, Australia

Chau Tran Campbelltown Hospital, NSW, Australia

Jane Tran Western Health/Monash Health, VIC, Australia

James Tria Novo Nordisk, NSW, Australia

Jessica Triay Bendigo Health, VIC, Australia

Lauren Tyack Fiona Stanley Hospital, WA, Australia

Mahesh Umapathysivam FMC, SA, Australia

Rita Upreti Monash Health, VIC, Australia

Amy Wagstaff Private Practice, VIC, Australia

Mawson Wang Concord Hospital, NSW, Australia

Anna Watts Monash Medical Centre, VIC, Australia Mor Aik Wee Peninsula Health, VIC, Australia

Tessa Weir University of Sydney, NSW, Australia

Jovitta William -, VIC, Australia

Penny Wolski Royal Brisbane and Women's Hospital, QLD, Australia

Lai Wong Private Practice, QLD, Australia

Anna Wood Royal Darwin Hospital, NT, Australia

Elizabeth Wootton Austin Health, VIC, Australia

Yu-Fang Wu Westmead Hospital, NSW, Australia

Katherine Wyld Redcliffe Hospital, QLD, Australia

Ling Yan Dalian Jinxi Medical Technology Co., Ltd, LIAONING, China

Sin Dee Yap Royal Darwin Hospital, NT, Australia

Christopher Yates Royal Melbourne Hospital, VIC, Australia

Bu Yeap University of Western Australia, WA, Australia

Jeffrey Zajac University of Melbourne, VIC, Australia

Jasmine Zhu St Vincent's Hospital Melbourne, VIC, Australia

	NOTES	
ESA Seminar 2022 Booklet	Supported by 🔱 NOVARTIS	31 P a g e

ESA CLINICAL WEEKEND

SAVE THE DATE

11 - 13 NOVEMBER 2022 RYDGES LATIMER CHRISTCHURCH, NEW ZEALAND



www.esaclinicalweekend.org.au

ESA-SRB-APEG-NZSE ASM 2022



13[™] – 16[™] NOVEMBER, 2022 Te Pae, Christchurch, New Zealand

Save the date!

www.esa-srb-apeg-nzse.org

Artist: FinDac I Title: Kaitiaki. Photographer: A Walsh













EVENITY® works differently* to treat osteoporosis

*EVENITY builds bone rapidly by simultaneously increasing bone formation and decreasing bone resorption with 12 monthly doses in patients who need it the most¹

> **PBS Information:** Authority Required as treatment for severe established osteoporosis. Criteria Apply. Refer to PBS Schedule for full information.

FORMATION

RESORPTION

Refer to full Product Information before prescribing – available from Amgen Australia Ph: 1800 803 638 or at www.amgen.com.au/Evenity.Pl

For more information on EVENITY[®], or to report an adverse event or product complaint involving EVENITY[®], please contact Amgen Medical Information on 1800 803 638 or visit www.amgenmedinfo.com.au

This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

EVENITY MINIMUM PRODUCT INFORMATION. INDICATIONS: Treatment of osteoporosis in postmenopausal women at high risk of fracture. Treatment to increase bone mass in men with osteoporosis at high risk of fracture. CONTRAINDICATIONS: Uncorrected hypocalcaemia. Hypersensitivity to romosozumab, CHO-derived proteins or any component. PRECAUTIONS: Correct hypocalcaemia prior to initiating therapy. Monitor patients for signs and symptoms. Adequately supplement intake of calcium and vitamin D. Initiate appropriate therapy and discontinue use if anaphylactic or other clinically significant allergic reaction occurs. Consider the benefitrisk in patients at increased risk for myocardial infarction or stroke. Instruct patients to watch for symptoms of myocardial infarction and stroke and to seek prompt medical attention if symptoms occur. Assess cardiovascular risk factors prior to treatment. A patient's suitability for treatment should be based on individual benefitrisk assessment. Consider relative benefits and risks of treatment in patients at high cardiovascular risk. Treatment should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Discontinue use if myocardial infarction or stroke occurs during therapy, Evaluate patients for risk factors for osteonecrosis of the jaw (ONJ); use with caution in these patients. Consider discontinuation if osteonecrosis of the jaw occurs. Rare reports of atypical femoral fractures. ADVERSE EFFECTS: Common: nasopharyngitis, arthralgia, back pain, pain in extremity, fall, headache, hypertension, viral upper respiratory tract infection, osteoarthritis, influenza, musculoskeletal pain, upper respiratory tract infection, muscle spasms, dizziness, constipation, cough, urinary tract infection, myalgia, diarrhoea, confusion, gastritis, upper abdominal pain, spinal osteoarthritis, bronchitis, peripheral oedema, asthenia, dyslipidaemia, neck pain, cataract, paraesthesia. DOSAGE AND ADMINISTRATION: Subcutaneous injection of 210 mg, once every month for 12 doses. To administer 210 mg, give two subcutaneous injections. Ensure adequate intake of calcium and vitamin D. After completing therapy, transition to antiresorptive osteoporosis therapy. No dose adjustment required in the elderly or in renal impairment. PRESENTATION: Pre-filled syringe, supplied as a 2-pack. Refer to full Product Information before prescribing - available from Amgen Australia Ph: 1800 803 638 or at www.amgen.com.au/Evenity.Pl. Reference: 1. EVENITY® (romosozumab) Approved Product Information. Available at: www.amgen.com.au/Evenity.Pl

Amgen Australia Pty Ltd, Sydney NSW 2000. ABN 31 051 057 428. Phone: 02 9870 1333. www.amgen.com.au. AU-15171. Approved October 2021.

